Argenx Se Stock News

January 3 , 202 2 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a

argenx SE (NASDAQ:ARGX) Equities research analysts at Piper Sandler increased their FY2021 earnings per share estimates for shares of argenx in a note issued to investors on Monday, December 20th. Piper Sandler analyst E. Tenthoff now expects that the company will earn ($8.04) per share for the year, up from their prior estimate of []

argenx received FDA approval for Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis. The label looks very favorable, and the only negative is that patients who do not have AChR

H.C. Wainwright Stick to Their Buy Rating for Argenx Se

The recent approval of this drugmaker's first product is giving reasons to cheer now, but what about down the road?

Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Federal Reserve, last week, said it will be acce

Some of the stocks that may grab investor focus today are: Wall Street expects Carnival Corporation (NYSE: CCL) to report a quarterly loss at $1.27 per share on revenue of $1.34 billion before the

The recent approval of this drugmaker's first product is giving reasons to cheer now, but what about down the road?

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news. Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE''s (NASDAQ: ARGX ) efgartigimod for the treatment of generalized myasthenia gravis. AstraZeneca plc (NASDAQ: AZN ) and Amgen, Inc. (NASDAQ: AMGN ) announced an FDA nod for their Tezspire as a treatment option for severe asthma for those aged 12 years and older. Bristol-Myers Squibb Company ''s (NYSE: BMY ) Orencia was approved for the prophylactic treatment of acute graft-versus-host disease. Calliditas Therapeutics AB (publ) (NASDAQ: CALT ) scored an FDA win for Tarpeyo, the first-approved treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. Galera Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that its partner argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. These patients represent approximately 85% of the total gMG population 1 . With this regulatory milestone, VYVGART is the first and only FDA-approved neonatal Fc receptor (FcRn) blocker.

VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on t

BREDA, Netherlands--(BUSINESS WIRE)--Regulatory News: argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. These patients represent appro

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral COVID-19 Antiviral Treatmen

Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.